Key clinical point: Cardiovascular risk stratification based on age, history of prior cardiovascular diseases, and Framingham risk score, along with additional insights from coronary artery calcium scoring (CACS), was feasible in patients with chronic myeloid leukemia (CML) treated with any tyrosine kinase inhibitors (TKI).
Major finding: During a median follow-up of 3.8 years, rates of major adverse cardiovascular events (MACE) in study-defined low-, intermediate-, and high-risk groups were 0%, 10%, and 19%, respectively. None of the patients reclassified from intermediate to low risk by CACS experienced MACE.
Study details: This retrospective study included 88 patients with CML treated with any TKI.
Disclosures: No specific source of funding was identified. Some investigators, including the lead author, reported receiving honoraria and consultancy fees or serving on advisory boards of various pharmaceutical companies.
Source: Baggio D et al. Intern Med J. 2021;51(10):1736-40 (Oct 18). Doi: 10.1111/imj.15517.